Google Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Google Inc trades at $349.78 (market cap $4.24T), while Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B). The key difference: Google Inc is far larger — about 167.8× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| GOOG | RPRX | |
|---|---|---|
Market Cap | $4.24T | $25.27B |
Volume | 13,937,902 | 3,671,183 |
Sector | Media | Health |
52-Week High | $399.06 | $63.96 |
52-Week Low | $237.49 | $35.44 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $4.13T | $32.50B |
Dividend Yield | 0.26% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →